SK8282000A3 - Conjugates useful in the treatment of prostate cancer, pharmaceutical composition containing the same and use thereof - Google Patents

Conjugates useful in the treatment of prostate cancer, pharmaceutical composition containing the same and use thereof Download PDF

Info

Publication number
SK8282000A3
SK8282000A3 SK828-2000A SK8282000A SK8282000A3 SK 8282000 A3 SK8282000 A3 SK 8282000A3 SK 8282000 A SK8282000 A SK 8282000A SK 8282000 A3 SK8282000 A3 SK 8282000A3
Authority
SK
Slovakia
Prior art keywords
seq
ser
trans
hyp
chg
Prior art date
Application number
SK828-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Stephen F Brady
Dong-Mei Feng
Victor M Garsky
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SK8282000A3 publication Critical patent/SK8282000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SK828-2000A 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer, pharmaceutical composition containing the same and use thereof SK8282000A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (fr) 1997-12-02 1998-11-25 Conjugues utiles dans le traitement du cancer de la prostate

Publications (1)

Publication Number Publication Date
SK8282000A3 true SK8282000A3 (en) 2000-11-07

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
SK828-2000A SK8282000A3 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer, pharmaceutical composition containing the same and use thereof

Country Status (26)

Country Link
US (2) US20060148718A1 (fr)
EP (1) EP1036093A1 (fr)
JP (1) JP2001525337A (fr)
KR (1) KR100580137B1 (fr)
CN (1) CN1181092C (fr)
AR (1) AR016427A1 (fr)
AU (1) AU744652B2 (fr)
BG (1) BG65486B1 (fr)
BR (1) BR9815116A (fr)
CA (1) CA2311615A1 (fr)
DZ (1) DZ2665A1 (fr)
EA (1) EA002745B1 (fr)
EE (1) EE200000333A (fr)
HR (1) HRP20000367A2 (fr)
HU (1) HUP0100350A3 (fr)
ID (1) ID24735A (fr)
IL (1) IL136167A0 (fr)
IS (1) IS5502A (fr)
NO (1) NO20002804L (fr)
NZ (1) NZ504615A (fr)
PE (1) PE20000009A1 (fr)
PL (1) PL197006B1 (fr)
SK (1) SK8282000A3 (fr)
TR (1) TR200002260T2 (fr)
TW (1) TW577897B (fr)
WO (1) WO1999028345A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1144011T3 (da) * 1998-12-11 2010-07-05 Coulter Pharm Inc Pro-drug-forbindelser og fremgangsmåde til fremstilling deraf
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
EP3388086B1 (fr) 2007-08-17 2020-10-07 Purdue Research Foundation Conjugués comprenant un ligand du psma et un lieur et procédés pour leur utilisation
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CA2882019C (fr) * 2012-08-15 2021-02-09 Visen Medical, Inc. Agents d'antigenes specifiques de la prostate et leurs procedes d'utilisation pour l'imagerie du cancer de la prostate
JP2016500058A (ja) * 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
CN105229742A (zh) 2013-04-30 2016-01-06 惠普发展公司，有限责任合伙企业 存储器访问速率
KR102282378B1 (ko) 2013-10-18 2021-07-27 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CA3203072A1 (fr) 2020-12-22 2022-06-30 Andrea CASAZZA Composes comprenant une fraction tetrapeptidique
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (fr) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2265476A1 (fr) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugues utiles dans le traitement du cancer de la prostate
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
CN1181092C (zh) 2004-12-22
US20060148718A1 (en) 2006-07-06
NO20002804L (no) 2000-07-21
HUP0100350A2 (hu) 2001-08-28
BG104563A (en) 2001-04-30
CA2311615A1 (fr) 1999-06-10
BR9815116A (pt) 2000-10-10
JP2001525337A (ja) 2001-12-11
NO20002804D0 (no) 2000-05-31
CN1284086A (zh) 2001-02-14
KR100580137B1 (ko) 2006-05-16
PL197006B1 (pl) 2008-02-29
HUP0100350A3 (en) 2001-09-28
TR200002260T2 (tr) 2000-12-21
WO1999028345A1 (fr) 1999-06-10
AR016427A1 (es) 2001-07-04
TW577897B (en) 2004-03-01
AU1612399A (en) 1999-06-16
US20070021350A1 (en) 2007-01-25
KR20010032687A (ko) 2001-04-25
HRP20000367A2 (en) 2000-12-31
ID24735A (id) 2000-08-03
AU744652B2 (en) 2002-02-28
DZ2665A1 (fr) 2003-03-22
NZ504615A (en) 2003-05-30
BG65486B1 (bg) 2008-09-30
PL340768A1 (en) 2001-02-26
EA200000603A1 (ru) 2000-12-25
EE200000333A (et) 2001-08-15
EP1036093A1 (fr) 2000-09-20
IL136167A0 (en) 2001-05-20
IS5502A (is) 2000-05-19
EA002745B1 (ru) 2002-08-29
PE20000009A1 (es) 2000-01-27

Similar Documents

Publication Publication Date Title
AU715632B2 (en) Conjugates useful in the treatment of prostate cancer
US20060148718A1 (en) Conjugates useful in the treatment of prostate cancer
US20020103136A1 (en) Conjugates useful in the treatment of prostate cancer
AU726434B2 (en) Conjugates useful in the treatment of prostate cancer
AU740597B2 (en) Conjugates useful in the treatment of prostate cancer
US5998362A (en) Conjugates useful in the treatment of prostate cancer
US6174858B1 (en) Conjugates useful in the treatment of prostate cancer
US20070244055A1 (en) Conjugates useful in the treatment of prostate cancer
JP2000506494A (ja) 良性前立腺過形成の治療に有用な複合体
US6127333A (en) Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) Conjugates useful in the treatment of prostate cancer
AU749063B2 (en) Conjugates useful in the treatment of prostrate cancer
MXPA00005434A (en) Conjugates useful in the treatment of prostate cancer
CZ20002056A3 (cs) Konjugáty použitelné v léčbě karcinomu prostaty